Dr Nora Disis, U Washington
At the recent European Cancer Congress in Vienna, Austria, Dr Nora Disis (pictured right) kindly spoke with BSB about her clinical research with avelumab (Merck KGaA/Pfizer), a cancer immunotherapy that targets the programmed death-ligand 1 (PD-L1).
Dr Disis (@DrNDisis) who is Editor in Chief of JAMA Oncology (@JAMAOnc) and a Professor of Medicine at the University of Washington, presented a poster at the meeting (Abstract #2749) with updated data for the phase 1b trial of avelumab in relapsed/refractory ovarian cancer.
In addition to reviewing the results with avelumab and in particular, the biomarker results for PD-L1 and CA125 expression, Dr Disis talks about why avelumab is different from other anti PD-L1 checkpoint inhibitors.
This is particularly important when considering a competitive and crowded marketplace where path-to-market strategies become more focused and critical. Certainly some of the issues discussed in detail present a nice case study of some the challenges facing pharma companies when you are 5th, 6th or more to market. Differentiation becomes a key driver that needs to be considered and incorporated into the clinical development plan.
She also talked candidly with BSB about some of the challenges and opportunities for checkpoint inhibitors and the PD-L1 in ovarian cancer, a disease where there is a high unmet medical need for effective new therapies.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.
Which of these cakes will you choose?
Greetings from Vienna where we are gearing up for our coverage of the European Cancer Congress (Twitter #ECC2015).
We’ll be writing a “highlights” post for subscribers at the end of the day here on Saturday, Sunday and Monday, then will follow- up with more in-depth coverage after we have talked with experts about the data presented.
Checkpoint Inhibitors and Cancer Immunotherapy are not surprisingly hot topics at the meeting.
In case you missed it, this month’s episode of Novel Targets (are we really on show #6 already?!) takes us on a new branch of the journey looking at various aspects of cancer immunotherapy:
Boosting T cell production – Stepping on the Gas
In past shows, we’ve looked at unlocking the brakes (checkpoint inhibitors), immune biomarkers (MDSCs and STING pathway), an inflamed or immunologic tumour type (lung cancer), a non-inflamed tumour type (prostate cancer), adoptive cell therapies and now it’s time for something really different… what happens when we literally step on the gas with immune agonists?
That’s the theme of the latest show – listen to Episode 6 on SoundCloud or iTunes (open access thanks to our sponsors, Genentech).
This article focuses on more detailed background and show notes for BSB subscribers.
It’s an important topic that is both simple in concept to understand and yet highly complex in terms of optimising therapy.
It’s time to take a deeper dive…
Subscribers can log-in to learn more insights.